Clinical trialPhase 1 / Phase 2Unknown
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
A Phase I/II Dose Escalation Study to Evaluating the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG2001 Tosilate Tablets in Participants With KRAS Mutated Advanced Solid Tumours
- Outcome
- Outcome unknown
- Phase
- Phase 1 / Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- 10 August 2023
- Expected end
- February 2026
- Enrollment
- 110 participants
- Sites
- 1
- Primary outcomes
- Dose Limiting Toxicity (DLT); Incidence of Treatment-Emergent Adverse Events
- Sponsor
- Industry
- Results posted
- No
- Last update
- 6 March 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.